Newer evidence from the POP-RT phase III trial did show that pelvic nodal radiation for high-risk, locally advanced prostate ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

A randomized trial compared short-term androgen deprivation with high-dose radiotherapy (STADT-RT) and high-dose radiation therapy alone in localized prostate cancer.

Prostate cancer diagnoses have risen by almost a tenth in a year. Some 58,218 men in England were diagnosed with the disease last year – up by almost 5,000 on the year before – official data has ...

Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...

In men with prostate cancer, prophylactic whole pelvic radiotherapy does not improve OS compared to prostate-only dose-escalated radiotherapy.

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

Patients were more likely to have higher five-year and overall survival rates if their state had expanded Medicaid, ...

Higher BMI was associated with improved survival among patients with prostate cancer, especially those with metastatic disease.

Key Takeaways A new drug combo is more effective in treating advanced prostate cancerThe targeted drug niraparib added to hormone therapy slowed cancer growth and symptom progressionSigns show the ...

Men whose fathers diagnosed with prostate cancer at an early age faced a fourfold higher risk for early-onset prostate cancer, with a particularly elevated risk for high Gleason score disease. Also, ...

This early stage is often detected through routine screenings, such as a prostate-specific antigen (PSA) blood test and a digital rectal exam (DRE), before any symptoms arise. Because the disease is ...